| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal ID2701: Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 3 therapies |
|
Medicine details |
|
| Medicine name | belantamab mafodotin (Blenrep®) |
| Formulation | 100 mg powder for concentrate for solution for infusion |
| Reference number | 4389 |
| Indication | Monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy |
| Company | GlaxoSmithKline UK |
| BNF chapter | Immunological products & vaccines |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/05/2021 |
| NICE guidance | ID2701: Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 3 therapies |